COMPANY
3Helix
NIH awards 3
- NIH award 5R44OD021986-03 FY2020: $713,771 awarded for that fiscal year; activity R44 (SBIR); PI BENNINK, LUCAS LOUIS; recipient as written: 3HELIX, INC., SALT LAKE CITY, UT. Novel peptide reagents for imaging damage source ↗
- NIH award 2R44OD021986-02 FY2019: $704,620 awarded for that fiscal year; activity R44 (SBIR); PI BENNINK, LUCAS LOUIS; recipient as written: 3HELIX, INC., SALT LAKE CITY, UT. Novel peptide reagents for imaging damage source ↗
- NIH award 1R43OD021986-01 FY2016: $149,623 awarded for that fiscal year; activity R43 (SBIR); PI LI, YANG; recipient as written: 3HELIX, INC., SALT LAKE CITY, UT. New Peptide Reagent for Imaging Denatured Collagen in source ↗
Funding and NIH signals
- SEC Form D raise Raised $7.84M (Form D filed Sep 21, 2026). SEC Form D 0002001622-26-000003 (Sep 21, 2026)
Evidence (1 event)
- Sep 21, 2026 · SEC Form D 0002001622-26-000003
Name of Issuer: 3Helix, Inc.; CIK: 2001622; Address: Salt Lake City, UT; Submission type: D; Filing date: 2026-09-21; Industry Group: Biotechnology; Date of First Sale: 2026-08-31; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 7835028; Federal exemptions: 06b
- Sep 21, 2026 · SEC Form D 0002001622-26-000003